首例报告:胰腺癌患者接受锥形束CT引导立体定向自适应放疗(CT-STAR)
本文报告首例胰腺癌患者接受锥形束CT引导立体定向自适应放疗(CT-STAR)。患者为61岁女性转移性胰腺癌,因原发胰腺肿块症状接受35 Gy/5次CT-STAR。每日行千伏级锥形束CT并编辑危及器官轮廓,自适应计划在全部5次治疗中均满足4个关键管腔胃肠道结构的硬性约束,而初始计划若使用将出现9次关键危及器官硬性约束违反。作者认为CT-STAR是胰腺癌立体定向自适应放疗的有前景模式。
要点
- 首例胰腺癌患者接受锥形束CT引导立体定向自适应放疗(CT-STAR),处方35 Gy/5次。
- 若使用初始计划将出现9次关键危及器官硬性约束违反。
- 自适应计划在全部5次治疗中满足4个关键管腔胃肠道结构的硬性约束。
核心结论
- 作者报告首例胰腺癌患者接受CT-STAR治疗成功。
- 此前胰腺癌消融性自适应放疗仅限于具备MR引导和CT-on-rails自适应SBRT技术与工作流程的诊所。
- 作者认为CT-STAR是胰腺癌立体定向自适应放疗的有前景模式。
研究设计与样本
- 本文为首例病例报告,报告1例61岁女性转移性胰腺癌患者接受CT-STAR。
- 处方剂量为35 Gy/5次。
- 模拟采用呼气末CT并口服及静脉肠道对比剂。
- 初始计划及每日自适应计划均遵循严格等毒性原则,牺牲覆盖以满足关键管腔胃肠道危及器官硬性约束。
- 每日治疗时获取千伏级锥形束CT,由放射肿瘤科医生编辑危及器官轮廓以反映患者当日解剖。
主要发现
- 若使用初始治疗计划,将出现9次关键危及器官硬性约束违反。
- 自适应计划在全部5次治疗中使全部4个关键管腔胃肠道结构满足硬性约束。
- 初始计划与自适应计划通过剂量体积直方图目标进行比较,并给予较优计划。
关键数值与推荐
- 处方剂量为35 Gy/5次。
- 初始计划若使用将导致9次关键危及器官硬性约束违反。
- 自适应计划在全部5次治疗中使全部4个关键管腔胃肠道结构满足硬性约束。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Online adaptive stereotactic radiotherapy allows for improved target and organ at risk (OAR) delineation and inter-fraction motion management via daily adaptive planning. The use of adaptive SBRT for the treatment of pancreatic cancer (performed until now using only MRI or CT on rails-guided adaptive radiotherapy), has yielded promising outcomes. Herein we describe the first reported case of cone beam CT-guided stereotactic adaptive radiotherapy (CT-STAR) for the treatment of pancreatic cancer. CASE PRESENTATION: A 61-year-old female with metastatic pancreatic cancer presented for durable palliation of a symptomatic primary pancreatic mass. She was prescribed 35 Gy/5 fractions utilizing CT-STAR. The patient was simulated utilizing an end-exhale CT with intravenous and oral bowel contrast. Both initial as well as daily adapted plans were created adhering to a strict isotoxicity approach in which coverage was sacrificed to meet critical luminal gastrointestinal OAR hard constraints. Kilovoltage cone beam CTs were acquired on each day of treatment and the radiation oncologist edited OAR contours to reflect the patient's anatomy-of-the-day. The initial and adapted plan were compared using dose volume histogram objectives, and the superior plan was delivered. Use of the initial treatment plan would have resulted in nine critical OAR hard constraint violations. The adapted plans achieved hard constraints in all five fractions for all four critical luminal gastrointestinal structures. CONCLUSIONS: We report the successful treatment of a patient with pancreatic cancer treated with CT-STAR. Prior to this treatment, the delivery of ablative adaptive radiotherapy for pancreatic cancer was limited to clinics with MR-guided and CT-on-rails adaptive SBRT technology and workflows. CT-STAR is a promising modality with which to deliver stereotactic adaptive radiotherapy for pancreatic cancer.
引用
- Kim M, Schiff JP, Price A, et al. The first reported case of a patient with pancreatic cancer treated with cone beam computed tomography-guided stereotactic adaptive radiotherapy (CT-STAR). Radiat Oncol. 2022. PMID: 36100866. doi:10.1186/s13014-022-02125-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。